A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Lilly

Status and phase: Completed; Phase 2

Conditions: Urologic Neoplasms

Treatments: Drug: ALIMTA; Drug: gemcitabine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00034593

4699

H3E-MC-JMEV

Details and patient eligibility

About

Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.
• You must have at least one tumor that can be physically measured or scanned by x-ray.
• You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.

Exclusion criteria

• You may not have used an experimental medicine or device within the past month.
• Cancer that has spread to your brain.
• If you are unwilling or unable to take folic acid or vitamin B12 supplements.